Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Femasys Inc. - Common Stock (NQ:FEMY)

0.5750 -0.0193 (-3.25%)
Streaming Delayed Price Updated: 11:04 AM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Femasys Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Third Quarter Financial Results for 2025
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
Will Showcase Latest Fertility Solutions 
From Femasys Inc.
Via GlobeNewswire
News headline image
Roadzen Inc. (NASDAQ: RDZN) Completes $7M India Financing at 100% Premium – Paves Path to Higher Valuation | More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
-- Femasys leverages Kebomed’s pan-European distribution strength to drive adoption of FemBloc permanent birth control in France and Benelux, unlocking significant market access -- 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed
Addition strengthens FemSperm family of products and enables gynecologists to offer complete in-office sperm handling for FemaSeed Intratubal Insemination 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
-- Following the Setup Kit, the Insemination Kit completes the sperm preparation portion of FemSperm enabling gynecology call point activation to drive revenue growth -- 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand
Expands international footprint with entry into Asia-Pacific, building on recent CE Mark and UK approvals 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Second Quarter Financial Results for 2025
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
--European CE mark approval of the entire FemBloc® system marks pivotal achievement in expanding safe, accessible and non-surgical permanent contraceptive options for women-- 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
Femasys continues to expand access and market share for its first-line infertility treatment option 
From Femasys Inc.
Via GlobeNewswire
News headline image
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
News headline image
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
First-in-world approval of FemBloc delivery system for women seeking permanent birth control 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
From Femasys Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.